Items where Author is "Lakis, Sotiris"

Kotoula, Vassiliki and Lakis, Sotiris and Vlachos, Ioannis S and Giannoulatou, Eleni and Zagouri, Flora and Alexopoulou, Zoi and Gogas, Helen and Pectasides, Dimitrios and Aravantinos, Gerasimos and Efstratiou, Ioannis and Pentheroudakis, George and Papadopoulou, Kyriaki and Chatzopoulos, Kyriakos and Papakostas, Pavlos and Sotiropoulou, Maria and Nicolaou, Irene and Razis, Evangelia and Psyrri, Amanda and Kosmidis, Paris and Papadimitriou, Christos and Fountzilas, George (2016) Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. PloS One, 11 (9). pp. e0163138. ISSN 1932-6203 (Gold OA)

Kotoula, Vassiliki and Karavasilis, Vasilios and Zagouri, Flora and Kouvatseas, George and Giannoulatou, Eleni and Gogas, Helen and Lakis, Sotiris and Pentheroudakis, George and Bobos, Mattheos and Papadopoulou, Kyriaki and Tsolaki, Eleftheria and Pectasides, Dimitrios and Lazaridis, Georgios and Koutras, Angelos and Aravantinos, Gerasimos and Christodoulou, Christos and Papakostas, Pavlos and Markopoulos, Christos and Zografos, George and Papandreou, Christos and Fountzilas, George (2016) Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Breast Cancer Research and Treatment, 158 (2). pp.307-321. ISSN 1573-7217 (PP OA)

Fountzilas, George and Giannoulatou, Eleni and Alexopoulou, Zoi and Zagouri, Flora and Timotheadou, Eleni and Papadopoulou, Kyriaki and Lakis, Sotiris and Bobos, Mattheos and Poulios, Christos and Sotiropoulou, Maria and Lyberopoulou, Aggeliki and Gogas, Helen and Pentheroudakis, George and Pectasides, Dimitrios and Koutras, Angelos and Christodoulou, Christos and Papandreou, Christos and Samantas, Epaminontas and Papakostas, Pavlos and Kosmidis, Paris and Bafaloukos, Dimitrios and Karanikiotis, Charisios and Dimopoulos, Meletios-Athanassios and Kotoula, Vassiliki (2016) TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. Oncotarget, 7 (22). pp.32731-32753. ISSN 1949-2553 (OA)